"Efficacy and safety of Valdoxan given orally once a day for 24 weeks in patients with Major Depressive Disorder." Open, national, multicentric clinical trial for the evaluation of the antidepressant efficacy and tolerability of Valdoxan and its additional clinical benefits for depressed patients.
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Servier
Most Recent Events
- 07 Apr 2022 Status changed from recruiting to completed.
- 06 Aug 2014 New trial record